covid treatment8 May 2022 09:34
Excalibur Medicines Ltd investment overview
Igraine has invested in Excalibur Medicines Ltd (“EML”), a subsidiary of Excalibur Healthcare Services Ltd. EML has secured exclusive rights to and owns the COVID-19 patents on a drug, AZD1656, which is being developed as a potential therapeutic for diabetics suffering from COVID-19.
As there are very few new therapeutics in development for COVID-19 and associated virally transmitted diseases (most research is in combining existing treatments) this has the potential to be highly attractive to big pharma and biotech buyers. Further, if the trials are successful, it is likely the drug will be effective for the general population in COVID -19 and in other respiratory diseases.
this is a massive statment for a group of highly, resected top in there feild profesers , one with a obe, to make.
as covid seems to be on the back foot at present with the goverment, i beleive , adz 1656, is being geared up for the winter months and next attack of covid.
as you are all aware, adz1656 will be worth a lot more as the need/demand grows.
croda was granted 15.9 mill to expand uk vaccine sites, ( croda rns,31/3/2022)
so, wheels are in motion for distibuation when needed.
the lack of news is very frustating, but, i for 1 , its a hold and build,
gla, hopefully our time will come.